Otros idiomas ARS Pharmaceuticals, Inc.

Acciones

SPRY

US82835W1080

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
8,35 ^USD	+3,21 %		-1,42 %	+52,37 %

18/04	Un iniciado de ARS Pharmaceuticals vendió acciones por valor de 928.005 dólares, según un reciente registro de la SEC	MT
18/04	Un iniciado de ARS Pharmaceuticals vendió acciones por valor de 928.005 dólares, según un reciente registro de la SEC	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	18/04
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	18/04
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing	10/04
ARS Pharmaceuticals Files Response to FDA Complete Response Letter For Neffy	03/04
ARS Pharmaceuticals Submits Response to FDA Letter for Neffy	03/04
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)	03/04
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)	03/04
ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)	03/04
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	21/03
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) added to S&P Biotechnology Select Industry Index	18/03
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy Investor Day	08/03
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day	07/03
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024	06/03
North American Morning Briefing : Stock Futures -2-	06/03
ARS Pharmaceuticals announces neffy meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study	27/02
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study	26/02
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study	26/02
ARS Pharmaceuticals Announces neffy Meets Primary Endpoints and Shows Rapid Symptom Control in Phase 2 Urticaria Clinical Study	26/02
ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024	22/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas ARS Pharmaceuticals, Inc.

Acciones

SPRY

US82835W1080

Otros idiomas

Filtros